Sutherland RL - Search Results

1

Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL, Musgrove EA. Caldon CE, et al. Among authors: sutherland rl. Cell Cycle. 2013 Feb 15;12(4):606-17. doi: 10.4161/cc.23512. Epub 2013 Jan 16. Cell Cycle. 2013. PMID: 23324395 Free PMC article.

2

Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1.

Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter LJ, Sutherland RL, Musgrove EA. Swarbrick A, et al. Among authors: sutherland rl. Oncogene. 2005 Jan 13;24(3):381-9. doi: 10.1038/sj.onc.1208188. Oncogene. 2005. PMID: 15489884

3

Cell cycle control in breast cancer cells.

Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Caldon CE, et al. Among authors: sutherland rl. J Cell Biochem. 2006 Feb 1;97(2):261-74. doi: 10.1002/jcb.20690. J Cell Biochem. 2006. PMID: 16267837 Review.

4

The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints.

Munoz MA, Saunders DN, Henderson MJ, Clancy JL, Russell AJ, Lehrbach G, Musgrove EA, Watts CK, Sutherland RL. Munoz MA, et al. Among authors: sutherland rl. Cell Cycle. 2007 Dec 15;6(24):3070-7. doi: 10.4161/cc.6.24.5021. Epub 2007 Sep 7. Cell Cycle. 2007. PMID: 18073532

5

Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Caldon CE, Sergio CM, Schütte J, Boersma MN, Sutherland RL, Carroll JS, Musgrove EA. Caldon CE, et al. Among authors: sutherland rl. Mol Cell Biol. 2009 Sep;29(17):4623-39. doi: 10.1128/MCB.00269-09. Epub 2009 Jun 29. Mol Cell Biol. 2009. PMID: 19564413 Free PMC article.

6

Cell cycle proteins in epithelial cell differentiation: implications for breast cancer.

Caldon CE, Sutherland RL, Musgrove E. Caldon CE, et al. Among authors: sutherland rl. Cell Cycle. 2010 May 15;9(10):1918-28. doi: 10.4161/cc.9.10.11474. Epub 2010 May 15. Cell Cycle. 2010. PMID: 20473028 Review.

7

Cyclin D as a therapeutic target in cancer.

Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Musgrove EA, et al. Among authors: sutherland rl. Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090. Nat Rev Cancer. 2011. PMID: 21734724 Review.

8

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Caldon CE, et al. Among authors: sutherland rl. Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7. Mol Cancer Ther. 2012. PMID: 22564725

9

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Caldon CE, Sergio CM, Sutherland RL, Musgrove EA. Caldon CE, et al. Among authors: sutherland rl. Cell Cycle. 2013 Feb 15;12(4):596-605. doi: 10.4161/cc.23409. Epub 2013 Jan 16. Cell Cycle. 2013. PMID: 23324394 Free PMC article.

10

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.

Kang J, Sergio CM, Sutherland RL, Musgrove EA. Kang J, et al. Among authors: sutherland rl. BMC Cancer. 2014 Jan 20;14:32. doi: 10.1186/1471-2407-14-32. BMC Cancer. 2014. PMID: 24444383 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

390 results

Search Page